Ann: Quarterly Activity Report & Appendix 4C, page-105

Within 2 years we will have proof of concept data with RC220 from the fully funded Phase 1a/b Trial, for both cardio protection and anti-cancer synergy. In fact, we can expect to receive updates well before trial completion. We will know whether bisantrene works soon enough.

I don’t think we’ll get bought out until after we have some Phase 2 data under our belts, but imo there’s no likely scenario where our SP is anywhere near this range come 2026 (for better or worse).

I’m not sure where you got ~9 years from. It’s never been Race’s goal to take bisantrene all the way to market.
I’d suggest freshening up on the November 2023 Strategic update.